Why the study?
Does ramipril lower the risk of cardiovascular events in high-risk patients with preexisting vascular disease?
Does ramipril lower the risk of cardiovascular events in high-risk patients with preexisting vascular disease?
Ramipril provides substantial cardiovascular benefits in high-risk patients with preexisting vascular disease, leading to early termination of the HOPE trial for efficacy.
An important article in this issue of the Journal describes the results of the Heart Outcomes Prevention Evaluation (HOPE) study, which are likely to have important implications for the treatment of cardiovascular disease.1 The findings indicate that ramipril, an angiotensin-converting–enzyme (ACE) inhibitor, substantially lowers the risk of death, heart attack, stroke, coronary revascularization, heart failure, and complications related to diabetes mellitus in a high-risk group of patients with preexisting vascular disease. The study was stopped early by the data and safety monitoring board because of the obvious benefit of ramipril. The results are remarkable both for the magnitude of the . . .
No takes yet. Share an insight, caveat, or question.
Gary S. Francis (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: